Based on these earlier findings, the present study was designed to assess the therapeutic effects of SMO inhibitor, PF-04449913 in a transgenic mouse model of myeloproliferative disease as well as possible molecular mechanisms underlying the effects, including its effects on splenomegaly, bone marrow fibrosis, allelic burden and alteration in cellular signaling pathways, and more importantly, its effects on the Hh signaling pathway in a JAK2V617F mouse model. This evidence concerns the gene SMO and myeloproliferative disorder.